Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class, masked, ...

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its ...

TU2218 is a novel oral dual inhibitor targeting TGFR1 and VEGFR2. TGF-ß and VEGF pathways are known to suppress the activity of immune checkpoint inhibitors (ICIs), so TU2218 is expected to improve ...

Former US President Jimmy Carter, who was diagnosed with melanoma that spread to his brain in 2015, has survived for nine ...

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on IDEAYA Biosciences (IDYA – Research Report). The associated ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Mural Oncology a clinical-stage oncology company focused on discovering and developing immunotherapies, held its first ...

The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

September marked Ovarian Cancer Awareness Month, highlighting the importance of early detection and the need for equitable ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...